WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Cantab Biopharmaceuticals Ltd
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Industrial Impact
QIAGEN and Neuron23™ | September 15, 2022
QIAGEN and Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase inhibitor for Parkinson’s disease. Under the new Master Collaboration Agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of bi...
Cell and Gene Therapy
Vaxart, Inc. | August 29, 2022
Vaxart, Inc. announced that Elaine J. Heron, Ph.D. was appointed to the Company’s Board of Directors, effective August 25, 2022. "Elaine has tremendous experience in life science research and development, sales and marketing, finance, and accounting, as well as corporate governance matters,” said Andrei Floroiu, Vaxart's Chief Executive Officer. "We welcome Elaine to Vaxart and the Board.” The Company also announced that Dr. Julie Che...
Industry Outlook
Businesswire | June 26, 2023
Enveda Biosciences, a biotechnology company discovering new medicines from natural sources, released the details of one of its foundational AI models, MS2Mol, in a pre-print posted on ChemRxiv. MS2Mol is designed to predict the structure of metabolites, which are the building blocks and breakdown products of the cell. Despite their essential role in all cell processes, it is estimated that less than 1% of all naturally-occurring metabolites are known to science. The ability of MS2Mol to ra...
iXCells Biotechnologies | September 30, 2022
iXCells Biotechnologies a high growth provider of cell-based products and discovery services to the academic, biotech and pharmaceutical communities worldwide, with special focus on primary and induced pluripotent stem cell derived cellular models, today announced receiving a growth investment from Connecticut-based Great Point Partners a private investment firm focusing on the healthcare industry. “iXCells is delighted to join GPP’s portfolio of ...
Cell and Gene Therapy, Medical
Whitepaper
Video
Research, Medical
Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE